GlassScriptPhysician profile
Jason Robert White
NPI 1700211828
$8,847.66
in general payments reported to CMS, 2019-2025
50 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,192 · 2022: $1,336 · 2023: $2,300 · 2024: $2,526 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,319.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,533.91 | 2021-2025 | |
| Sk Life Science, INC. | $484.92 | 2021-2024 | |
| Biogen, INC. | $426.41 | 2022-2024 | Vumerity, Tysabri, Avonex |
| Lundbeck LLC | $385.78 | 2021-2025 | Vyepti |
| Pfizer INC. | $376.63 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $343.59 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Jazz Pharmaceuticals INC. | $286.57 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $266.21 | 2021-2024 | |
| Neurelis, INC. | $262.39 | 2022-2024 | Valtoco |
| Ucb, INC. | $260.98 | 2021-2025 | Briviact |
| Acadia Pharmaceuticals INC | $242.45 | 2021-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $219.93 | 2022-2025 | Crexont, Lyvispah, Brekiya |
| Neurocrine Biosciences, INC. | $216.56 | 2021-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $193.03 | 2021-2025 | Emgality, Reyvow |
| Banner Life Sciences, LLC | $192.30 | 2022-2024 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.